Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label extension of Oxabact in primary hyperoxaluria (OC5-DB-02 extension)
2018-003576-12Phase 3Terminated
- Sponsor
- OxThera AB
- Start
- Nov 2018
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of oxalobacter formigenes in Primary hyperoxaluria (PH) and Not applicable, sponsored by OxThera AB. Primary endpoint: Change from baseline in kidney function (eGFR). Started Nov 2018; status: terminated.
02
Drugs
oxalobacter formigenes
03
Conditions
Primary hyperoxaluria (PH)Not applicable
Beyond the preview
Go deeper on 2018-003576-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003576-12.